Progesterone receptor modulators (PRMs) like mifepristone and gestrinone are medications used to treat endometriosis—a painful, estrogen-dependent condition where tissue similar to the womb lining grows outside the uterus—by altering progesterone activity to slow down tissue growth, though evidence of their efficacy remains low-certainty alongside notable side effects like hot flushes.
Endometriosis affects women during their reproductive years, triggering chronic pelvic pain, painful periods (dysmenorrhoea), and pain during sexual intercourse (dyspareunia). While conventional treatments range from surgical interventions to hormonal suppressants like gonadotropin-releasing hormone (GnRH) analogues, clinical investigators continue evaluating alternative drug classes. Among these are progesterone receptor modulators (PRMs)—a family of compounds including mifepristone, gestrinone, ulipristal acetate, vilaprisan, and asoprisnil—which alter how the hormone progesterone functions in human tissue to suppress ectopic endometrial lesions.
Updated clinical evidence compiled up to April 2026 sheds fresh light on how these medications stack up against standard placebos and older hormonal drugs. Yet, as health systems evaluate patient access and safety parameters, clinicians face a complex risk-benefit balance. Below is an exhaustive breakdown of what the latest clinical reviews reveal regarding PRMs.
In Plain English: The Clinical Takeaway
- What PRMs Do: Progesterone receptor modulators change how the hormone progesterone acts in the body, helping slow or stop the abnormal growth of uterine-like tissue outside the womb.
- Mifepristone vs. Placebo: Clinical trials show mifepristone may significantly reduce painful periods after three months of use, but it also carries a substantially higher risk of side effects like hot flushes.
- Gestrinone vs. Alternatives: Gestrinone may be less effective at treating painful periods than standard GnRH analogues (such as leuprorelin), though it may offer better relief for pain during sex and trigger fewer hot flushes.
Evaluating Efficacy: Mifepristone Against Placebo Controls
In the management of endometriosis, determining true drug efficacy requires rigorous double-blind, placebo-controlled trials. For the PRM mifepristone, data from a study involving 342 women demonstrated that the medicine may reduce dysmenorrhoea after three months of treatment. Expressed in statistical probability, if roughly 40% of patients taking a dummy treatment experience severe menstrual pain, that figure drops to between 3% and 10% for women taking mifepristone.
However, therapeutic gain comes with notable adverse events. Data from a 360-participant trial highlighted that mifepristone drastically increases the incidence of hot flushes, with an odds ratio indicating a steep climb in risk. Conversely, data showed little to no discernible difference in the prevalence of nausea between the treatment and placebo arms. Researchers remain uncertain whether mifepristone provides a meaningful reduction in dyspareunia, as current data quality for that specific endpoint sits at very low certainty.
Comparing Gestrinone to Standard Medical Treatments
When evaluating gestrinone, clinical comparisons shift toward established therapies like danazol and GnRH analogues. A study tracking 55 women over a six-month period found that gestrinone may be less efficient in treating painful periods than the GnRH analogue leuprorelin. Interestingly, the same study noted that gestrinone patients reported better relief from pain during sexual intercourse, alongside lower rates of hot flushes compared to the leuprorelin cohort.
When compared against danazol in trials encompassing 302 participants over six months, evidence regarding overall pelvic pain improvement, dysmenorrhoea scores, and hot flushes remains highly uncertain due to wide confidence intervals and small sample sizes. While nausea rates appeared roughly similar between gestrinone and danazol, the overall certainty of this evidence is low, underscoring the urgent need for larger trials.
| Medication Compared | Study Population | Primary Clinical Observation | Notable Adverse Effects |
|---|---|---|---|
| Mifepristone vs. Placebo | 342–360 participants (3 months) | May reduce painful periods significantly; uncertainty regarding pain during sex. | Significantly increased risk of hot flushes; little effect on nausea. |
| Gestrinone vs. Leuprorelin (GnRH Analogue) | 55 participants (6 months) | Less effective for painful periods, but may improve pain during sex. | Fewer hot flushes than leuprorelin; similar nausea rates. |
| Gestrinone vs. Danazol | 302 participants (6 months) | Uncertain effects on overall pelvic pain and dysmenorrhoea. | Uncertain impact on hot flushes; similar rates of nausea. |
Methodological Limitations and Funding Landscape
Interpreting clinical data on PRMs requires a careful look at methodological rigor. The overall certainty of evidence across these trials is graded as low to very low. Key vulnerabilities identified in these studies include small sample sizes, high or unclear rates of participant attrition, and inadequate blinding protocols where participants may have known which treatment they received.
Furthermore, publication bias remains a hurdle; for instance, trials testing the PRM asoprisnil were published only as short summaries devoid of usable quantitative results. Until larger, well-designed trials emerge comparing PRMs directly against modern standard-of-care therapies using validated pain-scoring metrics, widespread clinical adoption will likely remain restricted.
Contraindications & When to Consult a Doctor
Patients exploring hormonal management for endometriosis must undergo comprehensive evaluation by a qualified gynecologist or reproductive endocrinologist. PRMs are strictly contraindicated in individuals with known hypersensitivity to the compounds, patients with active liver disease, or those with certain hormone-sensitive malignancies. Because these medications alter hormonal pathways, they are generally contraindicated during pregnancy and breastfeeding.
You should consult a healthcare professional immediately if you experience severe, acute pelvic pain that does not respond to prescribed analgesics, unexplained vaginal bleeding, signs of severe hepatic dysfunction (such as yellowing of the skin or eyes, dark urine, or upper right abdominal pain), or persistent, debilitating psychological symptoms. Never alter or discontinue hormonal regimens without direct clinical supervision.
References
- Cochrane Database of Systematic Reviews – Progesterone receptor modulators for endometriosis (Up to April 2026).
